

AMENDED CLAIMS

received by the International Bureau on 13 December 2004 (13.12.04)
original claims 1-28, replaced by amended claims 1-27

1. A formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, GD1b, NANA, and sialic acid, for mediating inflammation.
2. The formulation of claim 1, comprising the ganglioside GD3.
3. The formulation of claim 1 or 2, comprising the ganglioside GM3.
4. The formulation of any one of claims 1 to 3, wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight.
5. The formulation of any one of claims 1 to 3, wherein the percentage of GM3 as a function of total gangliosides is at least 50% by weight.
6. The formulation of claim 1, comprising 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.
7. The formulation of claim 1 comprising about 80% GD3 and about 5% GM3 by weight based on total gangliosides.
8. The formulation of any one of claims 1 to 7, wherein mediating inflammation comprises mediating inflammation of the intestine, retina, or neuronal tissue.
9. The formulation of any one of claims 1 to 8, wherein mediating inflammation comprises preventing or treating an inflammatory disease.
10. The formulation of claim 9, wherein said inflammatory disease is selected from the group consisting of inflammatory bowel disorders, disorders arising from allergic responses, and diseases involving epithelial surface responses.

11. The formulation of any one of claims 1 to 10, in the form of a supplemented liquid or food.
12. The formulation of claim 11, wherein said supplemented liquid or food comprises infant formula or infant foods.
13. A method for mediating inflammation in a subject in need thereof comprising the step of providing the formulation of any one of claims 1-12 to said subject for oral consumption.
14. Use of the formulation of any one of claims 1-12 for the manufacture of a medicament for mediating inflammation.
15. The use of claim 14, wherein the medicament is formulated for oral administration.
16. A formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, GD1b, NANA, and sialic acid, for reducing plasma cholesterol level.
17. The formulation of claim 16, comprising the ganglioside GD3.
18. The formulation of claim 16, comprising the ganglioside GM3.
19. The formulation of any one of claims 16 to 18, wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight.
20. The formulation of any one of claims 16 to 18, wherein the percentage of GM3 as a function of total gangliosides is at least 50% by weight.

21. The formulation of claim 16, comprising 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.
22. The formulation of claim 16, comprising about 80% GD3 and about 5% GM3 by weight based on total gangliosides.
23. The formulation of any one of claims 16 to 22, in the form of a supplemented liquid or food.
24. The formulation of claim 23, wherein said supplemented liquid or food comprises infant formula or infant foods.
25. A method for reducing plasma cholesterol level in a subject in need thereof comprising the step of providing the formulation of any one of claims 16-24 to said subject for oral consumption.
26. Use of the formulation of any one of claims 16-24 for the manufacture of a medicament for reducing plasma cholesterol level.
27. The use of claim 26, wherein the medicament is formulated for oral administration.

DECLARATION SELON L'ARTICLE 19 (1)

The claims have been amended to more clearly define the invention, by limiting to specific gangliosides in the broad claims and by excluding GM1.